In this episode of DeviceTalks AI, we explore the advancements in AI-driven technologies in women's health and cancer diagnostics.

In our keynote interview, we speak with Michael Quick, Vice President of R&D and Innovation in Cytology & Oncology at Hologic. Quick shares his journey from a pre-med student to a leader in cytology innovation. He discusses the development and impact of Hologic’s Genius Digital Diagnostic Systems, the first FDA-approved digital cytology system, which leverages AI to enhance cervical cancer screening accuracy and efficiency. Michael emphasizes Hologic’s dedication to women's health and the critical role of AI in addressing the shortage of skilled cytologists, ensuring faster and more accurate diagnostics for patients worldwide. He also touches on the challenges and opportunities faced during the FDA approval process and the importance of early and collaborative engagement with regulatory bodies.

We also hear from Dr. Wael Yared, Chief Technology Officer at Tecan, who highlights Tecan's contributions to cancer research and diagnostics. Dr. Yared elaborates on the company's innovations in liquid biopsy and solid tissue biopsy workflows, which leverage AI to streamline processes and reduce errors. He emphasizes the significance of partnerships in driving medical advancements and the role of AI in personalized medicine and multiomic capabilities.

This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about Tecan visit, https://partnering.tecan.com

Please subscribe to DeviceTalks AI on all major podcast channels and subscribe to DeviceTalks on YouTube to ensure you never miss an episode.

Thank you for listening to DeviceTalks AI!

Hologic's FDA-cleared Genius Digital Dx Systems leads AI innovation in cervical cancer prevention

In this episode of AbbottTalks, Sandra Lesenfants, SVP of Abbott’s structural heart business, discusses the latest advancements in structural heart care, focusing on Abbott's transformative TriClip device for tricuspid regurgitation.

Lesenfants highlights Abbott’s commitment to patient-centered innovation, emphasizing the importance of creating solutions that meet patients’ needs through safe and effective technologies. She also shares Abbott’s approach to expanding access to minimally invasive therapies, particularly in underserved populations worldwide, and the role of physician partnerships in advancing structural heart interventions.

Lastly, Lesenfants underscores the company’s efforts to increase diversity in clinical trials, noting the importance of intentional inclusivity across gender and ethnicity to better serve diverse patient populations.

Thank you to Confluent Medical Technologies for sponsoring this episode of AbbottTalks. For more information on how Confluent Medical works with medical device companies, visit https://confluentmedical.com/.

Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.

Abbott’s Lesenfants shares TriClip progress, patient-centered innovation & clinical trial diversity

The DeviceTalks Podcast Network delivers news, insights and commentary from MedTech industry leaders, primarily from the largest OEMs in healthcare. Our podcasts will inspire MedTech professionals to create better MedTech devices and companies.

Explore the DeviceTalks Podcast Network, home to more than 11 podcasts:

• DeviceTalks Weekly
• AbbottTalks
• Boston Scientific Talks
• DeviceTalks AI
• IntuitiveTalks
• MedtechWOMEN Talks
• MedtronicTalks
• Neuro Innovation Talks: J&J MedTech Neuro
• Structural Heart Talks: Edwards Lifesciences
• Ortho Innovation Talks: Zimmer Biomet
• StrykerTalks

WATCH our video podcasts on www.youtube.com/@DeviceTalks

Connect with the hosts:
Tom Salemi, Editorial Director, DeviceTalks https://www.linkedin.com/in/tom-salemi-7118948/
Kayleen Brown, Managing Editor, DeviceTalks https://www.linkedin.com/in/kayleenbrown/

Learn more about DeviceTalks - Podcasts • Conferences • Webinars - www.devicetalks.com

Hologic's FDA-cleared Genius Digital Dx Systems leads AI innovation in cervical cancer prevention

DeviceTalks

Related tracks